Holen Sie sich die Stockscreener-App
2.795
9.72%
-0.301
Handel nachbörslich:
2.66
-0.135
-4.83%
Gt Biopharma Inc Aktie (GTBP) Neueste Nachrichten
GT Biopharma (GTBP) Enhances Board with New Appointment | GTBP S - GuruFocus
GT Biopharma appoints David Mun-Gavin to board of directors By Investing.com - Investing.com South Africa
GT Biopharma appoints David Mun-Gavin to board of directors - Investing.com
GT Biopharma Appoints New Member To Its Board Of Directors - MarketScreener
GT Biopharma (GTBP) Enhances Board with New Appointment | GTBP Stock News - GuruFocus
GT Biopharma Appoints New Member to its Board of Directors - GlobeNewswire
GT Biopharma Strengthens Board Before Critical Cancer Drug Results: Banking Expert Joins NK Cell Pioneer - Stock Titan
GTBP: GT Biopharma Plans Major Stock Sale | GTBP Stock News - GuruFocus
GT Biopharma registers 120.6M shares for resale by selling stockholders - MSN
GT Biopharma Amends Share Purchase Agreement - TipRanks
GT Biopharma Reports Improved Quarterly Losses - TipRanks
GT Biopharma Expands Convertible Preferred Stock Offering - TipRanks
The Escalator: Zealand Pharma, GT Biopharma, PointClickCare and more - Medical Marketing and Media
This Natural Killer Treatment Could Help Transform How Cancer is Treated - Baystreet.ca
GT Biopharma, Inc. - MENAFN.com
GT Biopharma advances to next trial phase for cancer therapy By Investing.com - Investing.com South Africa
Ellis Martin Report: Goliath Resources Limited (CVE:GOT) Continues to Provide High Grade Gold Discoveries at Surebet in British Columbia - ABN Newswire
Ellis Martin Report: GT Biopharma Inc's (NASDAQ:GTBP) Michael Breen: Targeting Cancer Cells with a Natural Killer Based Immunotherapy - ABN Newswire
Stocks In Play - Baystreet.ca
Stocks In Play: GT Biopharma, Inc. By Baystreet.ca - Investing.com Canada
Ellis Martin Report: Blue Lagoon Resources (CNSX:BLLG) Weeks Away from Gold Production at the Dome Mountain Project - ABN Newswire
GT Biopharma advances to next trial phase for cancer therapy - Investing.com Australia
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals - marketscreener.com
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 - GlobeNewswire
GT Biopharma Phase 1 Trial Reveals Early Success: Cancer Drug Shows Safety and Immune Activation - Stock Titan
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - Benzinga
GT Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GT Biopharma appoints new board member By Investing.com - Investing.com Nigeria
GT Biopharma (GTBP) Welcomes New Board Member Andrew Ritter | GTBP Stock News - GuruFocus
TSX Yet to Run out of Steam - The Globe and Mail
GT Biopharma appoints new board member - Investing.com
GT Biopharma Strengthens Board with Biotech Exit Expert Andrew Ritter: 3 Successful Company Sales - Stock Titan
GT Biopharma adds Hilary Kramer to Board of Directors By Investing.com - Investing.com South Africa
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors - GuruFocus
GT Biopharma adds Hilary Kramer to Board of Directors - Investing.com
$12B Portfolio Expert Hilary Kramer to Guide NK Cell Pioneer GT Biopharma's Clinical Expansion - Stock Titan
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors | GTBP Stock News - GuruFocus
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):